Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nolan Priedigkeit, M.D.

Concepts

This page shows the publications Nolan Priedigkeit has written about Humans.
Connection Strength

0.053
  1. Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases. JCI Insight. 2017 09 07; 2(17).
    View in: PubMed
    Score: 0.009
  2. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. JAMA Oncol. 2017 May 01; 3(5):666-671.
    View in: PubMed
    Score: 0.008
  3. Evolutionary signatures amongst disease genes permit novel methods for gene prioritization and construction of informative gene-based networks. PLoS Genet. 2015 Feb; 11(2):e1004967.
    View in: PubMed
    Score: 0.007
  4. Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype. Oncogene. 2021 02; 40(7):1318-1331.
    View in: PubMed
    Score: 0.003
  5. ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis. BMC Med. 2020 11 19; 18(1):349.
    View in: PubMed
    Score: 0.003
  6. Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells. Cancer Res. 2021 01 15; 81(2):268-281.
    View in: PubMed
    Score: 0.003
  7. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. J Natl Cancer Inst. 2019 04 01; 111(4):388-398.
    View in: PubMed
    Score: 0.002
  8. Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. Mol Cancer Res. 2019 02; 17(2):457-468.
    View in: PubMed
    Score: 0.002
  9. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann Oncol. 2018 04 01; 29(4):872-880.
    View in: PubMed
    Score: 0.002
  10. The CARMA3-Bcl10-MALT1 Signalosome Drives NF?B Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer. Cancer Res. 2018 03 01; 78(5):1225-1240.
    View in: PubMed
    Score: 0.002
  11. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer. Clin Cancer Res. 2017 Mar 15; 23(6):1552-1563.
    View in: PubMed
    Score: 0.002
  12. Forkhead Box Q1 Is a Novel Target of Breast Cancer Stem Cell Inhibition by Diallyl Trisulfide. J Biol Chem. 2016 Jun 24; 291(26):13495-508.
    View in: PubMed
    Score: 0.002
  13. Comprehensive evaluation of fusion transcript detection algorithms and a meta-caller to combine top performing methods in paired-end RNA-seq data. Nucleic Acids Res. 2016 Mar 18; 44(5):e47.
    View in: PubMed
    Score: 0.002
  14. Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA. Neoplasia. 2014 Jan; 16(1):97-103.
    View in: PubMed
    Score: 0.002
  15. Morbid obesity resulting from inactivation of the ciliary protein CEP19 in humans and mice. Am J Hum Genet. 2013 Dec 05; 93(6):1061-71.
    View in: PubMed
    Score: 0.002
  16. Who's driving anyway? Herculean efforts to identify the drivers of breast cancer. Breast Cancer Res. 2012 Oct 31; 14(5):323.
    View in: PubMed
    Score: 0.002
  17. Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function. PLoS One. 2010 Sep 09; 5(9).
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.